Key Points
-
Nuclear factor of activated T cells (NFAT) is a family of closely related transcription factors that are ubiquitously expressed in mammalian cells and tissues. NFAT1–4 are regulated by the calcium-sensitive phosphatase calcineurin, which induces nuclear translocation and transcriptional activation.
-
The transcriptional activity of NFATs is primarily regulated by phosphorylation that in turn determines subcellular localization. Maintenance kinases such as dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) and casein kinase 1 phosphorylate cytoplasmic NFATs and prevent nuclear translocation, whereas export kinases such as DYRK1 and glycogen synthase kinase 3 phosphorylate nuclear NFATs and promote their export.
-
Overexpression and increased transcriptional activity of NFAT isoforms has been detected in various human solid tumours and cell lines, as well as haematological malignancies. This leads to the induction of genes that promote cellular phenotypes that are associated with tumour progression, such as proliferation, survival, migration and invasion phenotypes.
-
NFAT isoforms promote the migration and invasion of tumour cells, prerequisites for metastatic dissemination. These phenotypes are mediated by the transcriptional induction of NFAT target genes in tumour cells, such as prostaglandin E2 and lysophosphatidic acid.
-
NFATs are directly implicated in promoting tumour angiogenesis. In endothelial cells NFATs are activated by vascular endothelial growth factor A and promote vessel formation by inducing pro-angiogenic genes such as cyclooxygenase 2.
-
The activation of NFATs in tumour cells and the tumour microenvironment induces soluble factors that function through both paracrine and autocrine mechanisms to promote tumour progression.
-
Inactivation of NFATs decreases tumour formation. This is consistent with pathophysiological settings of increased expression of the calcineurin inhibitor Down syndrome candidate region 1, which attenuates the activation of NFATs and reduces tumour incidence.
-
Inhibition of NFAT activation using small-molecule inhibitors is predicted to suppress tumorigenesis. Paradoxically, patients receiving immunosuppressive therapy that blocks NFAT activity have a higher incidence of cancer.
-
Future cancer therapy targeting NFATs must take into account the cell type-specific phenotypes associated with deregulated the activation of NFATs.
Abstract
The roles of nuclear factor of activated T cells (NFAT) transcription factors have been extensively studied in the immune system. However, ubiquitous expression of NFAT isoforms in mammalian tissues has recently been observed, and a role for these transcription factors in human cancer is emerging. Various NFAT isoforms are functional in tumour cells and multiple compartments in the tumour microenvironment, including fibroblasts, endothelial cells and infiltrating immune cells. How do NFAT isoforms regulate the complex interplay between these compartments during carcinoma progression? The answers lie with the multiple functions attributed to NFATs, including cell growth, survival, invasion and angiogenesis. In addition to elucidating the complex role of NFATs in cancer, we face the challenge of targeting this pathway therapeutically.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Crabtree, G. R. & Olson, E. N. NFAT signaling: choreographing the social lives of cells. Cell 109 S67–79 (2002).
Hogan, P. G., Chen, L., Nardone, J. & Rao, A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 17, 2205–2232 (2003).
Shaw, J. P. et al. Identification of a putative regulator of early T cell activation genes. Science 241, 202–205 (1988).
Jauliac, S. et al. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nature Cell Biol. 4, 540–544 (2002). This is the first study to demonstrate that NFATs are pro-migration and invasion transcription factors in breast cancer.
Medyouf, H. et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nature Med. 13, 736–741 (2007).
Ryeom, S. et al. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 13, 420–431 (2008).
Imamura, R. et al. Carboxyl-terminal 15-amino acid sequence of NFATx1 is possibly created by tissue-specific splicing and is essential for transactivation activity in T cells. J. Immunol. 161, 3455–3463 (1998).
Chuvpilo, S. et al. Multiple NF-ATc isoforms with individual transcriptional properties are synthesized in T lymphocytes. J. Immunol. 162, 7294–7301 (1999).
Chuvpilo, S. et al. Alternative polyadenylation events contribute to the induction of NF-ATc in effector T cells. Immunity 10, 261–269 (1999).
Chen, L., Glover, J. N., Hogan, P. G., Rao, A. & Harrison, S. C. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature 392, 42–48 (1998).
Lopez-Rodriguez, C., Aramburu, J., Rakeman, A. S. & Rao, A. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc. Natl Acad. Sci. USA 96, 7214–7219 (1999).
Miyakawa, H., Woo, S. K., Dahl, S. C., Handler, J. S. & Kwon, H. M. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc. Natl Acad. Sci. USA 96, 2538–2542 (1999).
Yang, T. T., Xiong, Q., Graef, I. A., Crabtree, G. R. & Chow, C. W. Recruitment of the extracellular signal-regulated kinase/ribosomal S6 kinase signaling pathway to the NFATc4 transcription activation complex. Mol. Cell. Biol. 25, 907–920 (2005).
Giffin, M. J. et al. Structure of NFAT1 bound as a dimer to the HIV-1 LTR κB element. Nature Struct. Biol. 10, 800–806 (2003).
Jain, J., McCaffrey, P. G., Valge-Archer, V. E. & Rao, A. Nuclear factor of activated T cells contains Fos and Jun. Nature 356, 801–804 (1992).
Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375–387 (2006).
Macian, F. NFAT proteins: key regulators of T-cell development and function. Nature Rev. Immunol. 5, 472–484 (2005).
Penna, A. et al. The CRAC channel consists of a tetramer formed by Stim-induced dimerization of Orai dimers. Nature 456, 116–120 (2008).
Oh-Hora, M. et al. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nature Immunol. 9, 432–443 (2008).
Prakriya, M. et al. Orai1 is an essential pore subunit of the CRAC channel. Nature 443, 230–233 (2006).
Feske, S. et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441, 179–185 (2006).
Yeromin, A. V. et al. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature 443, 226–229 (2006).
Cahalan, M. D. STIMulating store-operated Ca2+ entry. Nature Cell Biol. 11, 669–677 (2009).
Gwack, Y., Feske, S., Srikanth, S., Hogan, P. G. & Rao, A. Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes. Cell Calcium 42, 145–156 (2007).
Okamura, H. et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol. Cell 6, 539–550 (2000).
Zhu, J. & McKeon, F. NF-AT activation requires suppression of Crm1-dependent export by calcineurin. Nature 398, 256–260 (1999).
Beals, C. R., Sheridan, C. M., Turck, C. W., Gardner, P. & Crabtree, G. R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275, 1930–1934 (1997). The first study demonstrating that GSK3 is a nuclear export kinase for NFAT.
Neal, J. W. & Clipstone, N. A. Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. J. Biol. Chem. 276, 3666–3673 (2000).
Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550–562 (2009).
Okamura, H. et al. A conserved docking motif for CK1 binding controls the nuclear localizationof NFAT1. Mol. Cell. Biol. 24, 4184–4195 (2004).
Zhu, J. et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell 93, 851–861 (1998).
Chow, C. W., Dong, C., Flavell, R. A. & Davis, R. J. c-Jun NH2-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1. Mol. Cell. Biol. 20, 5227–5234 (2000).
Yang, T. T., Xiong, Q., Enslen, H., Davis, R. J. & Chow, C. W. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol. Cell. Biol. 22, 3892–3904 (2002).
Gwack, Y. et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 441, 646–650 (2006).
Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595–600 (2006). References 34 and 35 define DYRKs as the long-sought-after export and maintenance kinases for NFATs.
Nayak, A. et al. Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylase. J. Biol. Chem. 284, 10935–10946 (2009).
Terui, Y., Saad, N., Jia, S., McKeon, F. & Yuan, J. Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1. J. Biol. Chem. 279, 28257–28265 (2004).
Yoeli-Lerner, M. et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol. Cell 20, 539–550 (2005). This paper shows that, in breast cancer cells, NFAT1 is ubiquitylated by the E3 ligase MDM2, which targets it for degradation.
Yoeli-Lerner, M., Chin, Y. R., Hansen, C. K. & Toker, A. Akt/protein kinase B and glycogen synthase kinase-3β signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol. Cancer Res. 7, 425–432 (2009).
Neal, J. W. & Clipstone, N. A. A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J. Biol. Chem. 278, 17246–17254 (2003).
Buchholz, M. et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J. 25, 3714–3724 (2006).
Robbs, B. K., Cruz, A. L., Werneck, M. B., Mognol, G. P. & Viola, J. P. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol. Cell. Biol. 28, 7168–7181 (2008). This paper shows that, in fibroblasts, distinct NFAT isoforms have non-overlapping roles as oncogenes and tumour suppressors, as revealed in both in vitro studies and mouse models.
Marafioti, T. et al. The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br. J. Haematol. 128, 333–342 (2005).
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lin-Lee, Y. C. & Ford, R. J. Constitutive NF-κB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 106, 3940–3947 (2005).
Horsley, V., Aliprantis, A. O., Polak, L., Glimcher, L. H. & Fuchs, E. NFATc1 balances quiescence and proliferation of skin stem cells. Cell 132, 299–310 (2008).
Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442–454 (2002).
Jonsson, M., Dejmek, J., Bendahl, P. O. & Andersson, T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 62, 409–416 (2002).
Dejmek, J., Safholm, A., Kamp Nielsen, C., Andersson, T. & Leandersson, K. Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1α signaling in human mammary epithelial cells. Mol. Cell. Biol. 26, 6024–6036 (2006).
Rabinovitz, I. & Mercurio, A. M. The integrin α6β4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin- containing motility structures. J. Cell Biol. 139, 1873–1884 (1997).
Mercurio, A. M. & Rabinovitz, I. Towards a mechanistic understanding of tumor invasion-lessons from the α6β4 integrin. Semin. Cancer Biol. 11, 129–141 (2001).
Yiu, G. K. & Toker, A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J. Biol. Chem. 281, 12210–12217 (2006).
Chen, M. & O'Connor, K., L., Integrin α6β4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 24, 5125–5130 (2005).
Stracke, M. L. et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524–2529 (1992).
Yang, S. Y. et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 19, 603–608 (2002).
Liu, S. et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15, 539–550 (2009). A recent study that highlights the potent metastatic activity of autotaxin and its product LPA in breast cancer progression.
Zhang, H. et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration In vitro and causes tumor regression In vivo. Cancer Res. 69, 5441–5449 (2009).
Mott, J. D. & Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16, 558–564 (2004).
Nagy, J. A., Dvorak, A. M. & Dvorak, H. F. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2, 251–275 (2007).
Dvorak, H. F. Discovery of vascular permeability factor (VPF). Exp. Cell Res. 312, 522–526 (2006).
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003).
Hernandez, G. L. et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 193, 607–620 (2001).
Gupta, G. P. et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765–770 (2007).
Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005–1009 (2009).
Armesilla, A. L. et al. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol. Cell. Biol. 19, 2032–2043 (1999).
Cockerill, G. W. et al. Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood 86, 2689–2698 (1995).
Jinnin, M. et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nature Med. 14, 1236–1246 (2008). NFAT activation is shown to lead to expression of VEGFRs and downstream signalling in haemangiomas, which are highly vascularized benign lesions typically seen in children.
Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355, 165–169 (2000).
Baek, K. H. et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459, 1126–1130 (2009). References 69 and 6 reveal that DSCR1, a suppressor of calcineurin activity in endothelial cells, can function as a suppressor of tumour growth by attenuating NFAT activity and VEGFA induction, as observed in patients with Down's syndrome who have increased expression of DSCR1.
Qin, L. et al. Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway. Mol. Cancer Res. 4, 811–820 (2006).
Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E. & Alitalo, K. Lymphangiogenesis and cancer metastasis. Nature Rev. Cancer 2, 573–583 (2002).
Skobe, M. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med. 7, 192–198 (2001).
Karpanen, T. et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61, 1786–1790 (2001).
Kulkarni, R. M., Greenberg, J. M. & Akeson, A. L. NFATc1 regulates lymphatic endothelial development. Mech. Dev. 126, 350–365 (2009).
Norrmen, C. et al. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J. Cell Biol. 185, 439–457 (2009).
Campbell, J. J. & Butcher, E. C. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr. Opin. Immunol. 12, 336–341 (2000).
Butcher, E. C., Williams, M., Youngman, K., Rott, L. & Briskin, M. Lymphocyte trafficking and regional immunity. Adv. Immunol. 72, 209–253 (1999).
Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001). Chemokines and chemokine receptors are shown to be highly upregulated and functional for metastatic dissemination of breast cancer cells in this paper.
Karnoub, A. E. & Weinberg, R. A. Chemokine networks and breast cancer metastasis. Breast Dis. 26, 75–85 (2006).
Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557–563 (2007).
Wyckoff, J. et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64, 7022–7029 (2004).
Kaufman, D. B. et al. Immunosuppression: practice and trends. Am. J. Transplant 4 Suppl. 9, 38–53 (2004).
Martinez-Martinez, S. & Redondo, J. M. Inhibitors of the calcineurin/NFAT pathway. Curr. Med. Chem. 11, 997–1007 (2004).
Matsuda, S. & Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology 47, 119–125 (2000).
Liu, J. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 807–815 (1991).
Kiani, A., Rao, A. & Aramburu, J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 12, 359–372 (2000).
Rezzani, R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog. Histochem. Cytochem. 39, 85–128 (2004).
Dantal, J. & Soulillou, J. P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N. Engl. J. Med. 352, 1371–1373 (2005).
Aramburu, J. et al. Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. Mol. Cell 1, 627–637 (1998).
Aramburu, J. et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285, 2129–2133 (1999).
Noguchi, H. et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nature Med. 10, 305–309 (2004).
Karanam, B. V. et al. Disposition of L-732531, a potent immunosuppressant, in rats and baboons. Drug Metab. Dispos. 26, 949–957 (1998).
Abel, M. D. et al. ISATX247: a novel calcineurin inhibitor. J. Heart Lung Transplant 20, 161 (2001).
Brundage, R. A., Fogarty, K. E., Tuft, R. A. & Fay, F. S. Calcium gradients underlying polarization and chemotaxis of eosinophils. Science 254, 703–706 (1991).
Evans, J. H. & Falke, J. J. Ca2+ influx is an essential component of the positive-feedback loop that maintains leading-edge structure and activity in macrophages. Proc. Natl Acad. Sci. USA 104, 16176–16181 (2007).
Wei, C. et al. Calcium flickers steer cell migration. Nature 457, 901–905 (2009).
Yang, S., Zhang, J. J. & Huang, X. Y. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell 15, 124–134 (2009). This paper reveals that the store-operated calcium channels STIM1 and ORAI1 promote calcium signals that are required for cell migration.
Szado, T. et al. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc. Natl Acad. Sci. USA 105, 2427–2432 (2008).
Masuda, E. S., Imamura, R., Amasaki, Y., Arai, K. & Arai, N. Signalling into the T-cell nucleus: NFAT regulation. Cell Signal 10, 599–611 (1998).
Horsley, V. & Pavlath, G. K. NFAT: ubiquitous regulator of cell differentiation and adaptation. J. Cell Biol. 156, 771–774 (2002).
Amasaki, Y. et al. A constitutively nuclear form of NFATx shows efficient transactivation activity and induces differentiation of CD4+CD8+ T cells. J. Biol. Chem. 277, 25640–25648 (2002).
Ranger, A. M., Oukka, M., Rengarajan, J. & Glimcher, L. H. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 9, 627–635 (1998).
Graef, I. A., Chen, F., Chen, L., Kuo, A. & Crabtree, G. R. Signals transduced by Ca2+/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105, 863–875 (2001).
Rengarajan, J., Tang, B. & Glimcher, L. H. NFATc2 and NFATc3 regulate TH2 differentiation and modulate TCR-responsiveness of naive TH cells. Nature Immunol. 3, 48–54 (2002).
Acknowledgements
We thank members of the Toker laboratory for many useful discussions and suggestions. We apologize to colleagues whose work could not be cited owing to space limitations. The Toker laboratory is funded by grants from the US National Institutes of Health and National Cancer Institute, the Department of Defense and the Susan G. Komen Breast Cancer Foundation.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
National Cancer Institute Drug Dictionary
Pathway Interaction Database
FURTHER INFORMATION
Glossary
- Store-operated channels
-
Calcium channels in the plasma membrane that allow the influx of extracellular calcium in response to the emptying of intracellular calcium stores such as the ER. Also known as CRAC channels.
- Rel family transcription factors
-
Transcription factors with an N-terminal Rel-homology domain that is responsible for nuclear localization, dimerization and DNA binding.
- Priming kinase
-
A serine/threonine kinase (such as a casein kinase) that, by phosphorylating specific residues in proteins, enables the subsequent phosphorylation of additional residues downstream of the priming sites, typically mediated by distinct kinases.
- Sumoylation
-
Similar to ubiquitylation in that proteins are post-translationally modified with small ubiquitin-like modifier (SUMO). Unlike ubiquitylation, sumoylation does not target proteins for degradation, instead it facilitates nuclear–cytoplasmic shuttling, transcription and cell cycle progression.
- EMT
-
A complex process in which genetic and epigenetic events lead to epithelial cells acquiring a mesenchymal architecture concomitant with increased cell motility. Typically associated with the loss of E-cadherin expression.
- Hemidesmosomes
-
Rivet-like structures found in epithelial cells and also keratinocytes that attach these cells to the extracellular matrix. In epithelial cells, hemidesmosomes couple to integrins.
- Haemangioma
-
A benign self-involuting mass of proliferating endothelial cells that typically presents in children.
- VEGFR
-
A receptor tyrosine kinase on the surface of endothelial cells that activates downstream signalling pathways subsequent to binding VEGF. VEGFR1 is also known as FLT-1, and VEGFR2 is also known as KDR and FLK1.
- Chemokines
-
A family of secreted cytokines that regulate both immune surveillance and inflammatory responses on infection.
- Epstein-Barr virus
-
EBV. Herpesvirus that can transform B cells. It is implicated in the aetiology of several different lymphoid malignancies, such as Burkitt's lymphoma.
- Angiogenic switch
-
The transition of a non-vascularized solid tumour to a highly vascularized state following recruitment of blood vessels.
Rights and permissions
About this article
Cite this article
Mancini, M., Toker, A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9, 810–820 (2009). https://doi.org/10.1038/nrc2735
Issue Date:
DOI: https://doi.org/10.1038/nrc2735
This article is cited by
-
PPIA dictates NRF2 stability to promote lung cancer progression
Nature Communications (2024)
-
CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression
Cell Death & Disease (2023)
-
DDIAS, DNA damage-induced apoptosis suppressor, is a potential therapeutic target in cancer
Experimental & Molecular Medicine (2023)
-
The Significant Role of microRNAs in Gliomas Angiogenesis: A Particular Focus on Molecular Mechanisms and Opportunities for Clinical Application
Cellular and Molecular Neurobiology (2023)
-
Pou3f1 mediates the effect of Nfatc3 on ulcerative colitis-associated colorectal cancer by regulating inflammation
Cellular & Molecular Biology Letters (2022)